Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First-and second-line data from the BOLERO-4 study.

Cardoso F., Villanueva C., Royce M., Cruz F., Debled M., Hegg R., ...More

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35, (Summary Text) identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 35
  • Doi Number: 10.1200/jco.2017.35.15_suppl.1010
  • City: Illinois
  • Country: United States Of America
  • Istanbul University Affiliated: Yes